Tirzepatide ntụ ntụ nnukwu

Kedu ihe bụ Tilsiparatide?

Tirzepatide ntụ ntụ nnukwu bụ onye na - anabata glucagon-dị ka peptide-1 (GLP-1). Ma GIP na GLP-1 bụ homonụ nke eriri afọ na-emepụta ma nwee ike ịkwalite mmepụta insulin. Tirzepatide na-ejikọta mmetụta insulinotropic abụọ n'ime otu molekul ma na-anọchite anya otu ọgwụ ọhụrụ maka ọgwụgwọ ụdị ọrịa shuga 2.
Tirzepatide bụ GIP/GLP-1 dual agonist agonist nwere ọkara ndụ ihe dị ka ụbọchị 5 ma enwere ike inye ya otu ugboro n'izu. Nnwale SURPASS gosipụtara na tilsiparatide na-enye nkwalite ụlọ ọgwụ na njikwa glycemic na mbelata ibu yana profaịlụ nchekwa dị mma.
Dabere na nke a, nkwupụta nkwenye kachasị ọhụrụ nke American Diabetes Association na European Association for Study of Diabetes wepụtara tilsiparatide dị ka ọgwụgwọ kachasị dị irè maka njikwa shuga ọbara na mbelata ibu.
Tirzepatide bụ nke mbụ dual glucose-based insulinotropic peptide (GIP) na glucagon-dị ka peptide-1 (GLP-1) agonist nnabata. A na-enye Tirzepatide dị ka injection subcutaneous otu ugboro kwa izu, enwere ike ịhazigharị dose ahụ dabere na nnabata. Dabere na usoro ọmụmụ SURPASS ya, ọgwụ kachasị elu nke 15 mg nwere ike ibelata uru zuru oke nke HbA1C site na 1.6% ma e jiri ya tụnyere placebo. Na mgbakwunye na mmetụta hypoglycemic ya, ọmụmụ SURMOUNT-1 gbasara ndị ọrịa buru ibu na-enweghị ọrịa shuga gosiri na Tirzepatide na oke dose nke 15 mg nwere ike belata ibu onye ọrịa site na nkezi nke 22.5% (24 n'arọ). Ugbu a ọ bụ naanị ọgwụ na-ebelata ibu nke na-ebelata ibu karịa 20%.

Kedu ihe kpatara ọgwụ hypoglycemic nwekwara ike inye aka belata ibu?

Ihe mbụ ị ga-aghọta bụ na ọ bụghị ọgwụ niile na-egbochi ọrịa shuga nwere ike inyere gị aka ịkwụsị ibu. Metformin, ọgwụ nke mbụ a na-ahọrọ maka ụdị ọrịa shuga 2 n'ụwa niile, nwere mmetụta mbelata oke ibu, mana enwerekwa ọtụtụ ọgwụ ọrịa shuga nwere mmetụta bara uru.

Tirsiparatide na-akwalite njikwa glycemic site na ịgbalite GLP-1 na ndị na-anabata GIP. Glucagon-dị ka peptide-1 (GLP-1) na glucose-based insulinotropic polypeptide (GIP) bụ homonụ na-etinye aka na njikwa shuga ọbara. Mmetụta GLP-1 bụ isi bụ ịkwụsị agụụ site na ịhazi mmepụta insulin na igbu oge ịpụsị afọ. GIP gastric inhibitory peptide na-egbochi secretion acid gastric na motility nke afọ, ma nweekwa mmetụta ụfọdụ na ichekwa agwaetiti pancreatic na imezi insulin secretion. Ya mere, n'ikwu ya n'ụzọ dị mfe, mgbe ọgwụ a batara n'ahụ mmadụ, ọ na-enwe mmetụta abụọ nke ịkwụsị agụụ.

Na-ekpe ikpe site na data ekpughere n'oge na-adịbeghị anya, tilsiparatide nwere mmetụta mbelata oke ibu na akụkọ ihe mere eme ma bụrụkwa ọgwụ mbụ nwere mmetụta mbelata ịdị arọ nke ihe karịrị 20% nke ịdị arọ ahụ. N'ime usoro ọgwụgwọ ụlọ ọgwụ nke 3, mgbe izu 72 nke tilsiparatide gasịrị, nkezi nha nha nha nke isiokwu ndị dị na obere dose (5mg), ọkara-dose (10mg), na nnukwu dose otu (15mg) bụ 15%, 19.5% na 20.9% n'otu n'otu. , ma e jiri ya tụnyere 3.1% na otu placebo. N'ime otu etiti na nke dị elu, 50.1% na 56.7% nwere oke ibu karịa 20% n'otu n'otu. N'otu oge ahụ, profaịlụ nchekwa nke ọtụtụ dose dị iche iche dị ezigbo mma, na ugboro ole mmeghachi omume ọjọọ yiri nke placebo.

Nlele na mbelata ibu

Nnwale SURMOUNT-1
Nnwale SURMOUNT-1 gụnyere ndị okenye 2539 na-enweghị ụdị ọrịa shuga 2, buru oke ibu ma ọ bụ buru oke ibu, ma nwee opekata mpe 1 comorbidity. Ọnụ ọgụgụ isi ala bụ 104.8 n'arọ yana BMI pụtara 38 kg/m2. A na-edobe ndị ọrịa 1: 1: 1: 1 iji nata Zepbound 5 mg, 10 mg, 15 mg, ma ọ bụ placebo dị ka injections subcutaneous otu ugboro kwa izu maka izu 72. Isi njedebe bụ pasent mgbanwe nke ịdị arọ ahụ site na ntọala yana ọnụ ọgụgụ ndị ọrịa tụfuru opekata mpe 5% nke ịdị arọ ahụ ha na izu 72. N'ime ule SURMOUNT-1, Zepbound jikọtara ya na oke ibu ndị a ma e jiri ya tụnyere placebo na izu 72:
① Nkezi arọ ọnwụ: 15% (5mg), 19.5% (10mg), 20.9% (15mg) VS 3.1% (placebo).
② Pasent nke ndị ọrịa tụfuru opekata mpe 5% nke ịdị arọ ahụ ha: 85.1% (5mg), 88.9% (10mg), 90.9% (15mg) VS 34.5% (placebo).

Nnwale SURMOUNT-2
Nnwale SURMOUNT-2 gụnyere ndị okenye 938 nwere ụdị ọrịa shuga 2 bụ ndị buru oke ibu ma ọ bụ buru oke ibu. Ọnụ ọgụgụ isi ala bụ 100.7 n'arọ yana BMI pụtara 36.1 kg/m2. E kenyere ndị ọrịa na-enweghị usoro na nha 1: 1: 1 ịnata Zepbound 10 mg, 15 mg, ma ọ bụ placebo dị ka injections subcutaneous otu ugboro kwa izu maka izu 72. Isi njedebe bụ pasent mgbanwe nke ịdị arọ ahụ site na ntọala yana ọnụ ọgụgụ ndị ọrịa tụfuru opekata mpe 5% nke ịdị arọ ahụ ha na izu 72. Nsonaazụ gosiri na Tirzepatide (10mg na 15mg) nwetara oke ibu ibu karịa placebo na 72 izu ọgwụgwọ. Ọmụmụ ihe ahụ zutere njedebe njedebe nke isi na isi njedebe nke abụọ ma e jiri ya tụnyere placebo. E jiri ya tụnyere placebo (3.3%, 3.2 n'arọ), ndị ọrịa nọ n'ìgwè 10 mg tụfuru nkezi nke 13.4% (13.5 n'arọ) na ndị nọ na otu 15 mg tụfuru nkezi nke 15.7% (15.6 n'arọ).

Na mgbakwunye, 81.6% (10 mg) na 86.4% (15 mg) nke ndị na-ewere tilsiparatide tụfuru opekata mpe 5% nke ịdị arọ ahụ ha (ebe njedebe ọzọ nke isi), ma e jiri ya tụnyere 30.5% nke ndị na-ewere placebo. E belatara.

Data nnwale na ibelata shuga ọbara

Nsonaazụ nke nnwale SURPASS-AP-Combo na-egosi na iji tilsiparatide kwa izu nwere ike imeziwanye njikwa shuga ọbara n'ime ndị ọrịa nwere ụdị ọrịa shuga 2 (T2D) nke a ka na-achịkwa shuga ọbara nke ọma site na iji metformin ma na-anabata ya nke ọma.

Otu n'ime uru bụ isi nke nnwale a bụ na ọtụtụ n'ime ndị ọrịa debanyere aha sitere na China, nha nlele buru ibu, ọnụ ọgụgụ mmecha dị elu, na data enyere zuru oke. Ya mere, ule pụta nwere elu generalizability na-adakarị omume na mba m.

Ọnwụnwa ahụ enyochara ndị ọrịa T2D (≥18 afọ) ndị na-enwetaghị ọgwụgwọ insulin na ụlọ ọgwụ 66 na China, South Korea, Australia na India. Ngụkọta nke ndị ọrịa 917 mechara debanye aha (763 n'ime ha si China) na usoro 1: 1: Ekenyere ndị otu anọ n'usoro na nha 4: 1:

Tirsiparatide 5 mg kwa izu (n = 230);
tilsiparatide 10 mg kwa izu (n = 228);
tilsiparatide 15 mg kwa izu (n = 229);
Otu glargine insulin kwa ụbọchị (n = 230).

Isi njedebe nke ọmụmụ ihe ahụ bụ mgbanwe mgbanwe HbA1c adịghị ala.

Nsonaazụ nke ọmụmụ ahụ gosiri na site na mmalite ruo izu 40, ndị ọrịa na-ewere tilsiparatide nwere mbelata kacha nta n'akụkụ anọ (se) na HbA1c karịa ndị ọrịa na-ewere insulin glargine, n'agbanyeghị dose.

Mbelata nke HbA1c n'ime otu ndị ọrịa n'oge dị iche iche

E jiri ya tụnyere insulin glargine, ọnụ ọgụgụ ndị ọrịa nọ na tilsiparatide 5 mg, otu 10 mg na otu 15 mg nwetara HbA1c <7.0% n'ime izu 40 dị elu, 75.4%, 86.0% na 84.4% n'otu n'otu.

Oke nke ndị ọrịa na-enweta HbA1c <7.0%, ≤6.5%, <5.7% mgbaru ọsọ na izu 40

N'ime izu 40, ndị ọrịa nọ n'ụdị ọgwụ tilsiparatide niile gosipụtara oke ibu dị oke ibu, yana ọnụ ọgụgụ dị elu nke ndị ọrịa nọ n'ụdị tilsiparatide niile mezuru ebumnuche mbelata ibu ha ma e jiri ya tụnyere ndị nọ na glargine insulin. .

Ọnụ ọgụgụ nke ndị ọrịa na-enweta ihe mgbaru ọsọ ọnwụ arọ na izu 40

Nnwale ahụ kwuru na mmeghachi omume ọjọọ nke tilsiparatide na-adị nwayọọ ma na-agafeghị oke nke agụụ, afọ ọsịsa na ọgbụgbọ, na-enweghị akụkọ banyere hypoglycemia siri ike.

N'ozuzu, nnwale SURPASS-AP-Combo kwekọrọ na nsonaazụ ndị a kọrọ na ule usoro SURPASS gara aga, na-akwado nrụpụta na nchekwa nke tsiparatide na ọnụ ọgụgụ T2D na mpaghara Asia-Pacific, ọkachasị ndị ọrịa China.
Ọ bụghị naanị na tilsiparatide na-egosi mmetụta dị mma na-ewedata HbA1c karịa insulin glargine, mana a na-anabata ya nke ọma, ọ nwekwara ike imeziwanye mmetụta insulin ma nyere aka kwalite mmetụta mgbochi hyperglycemic.

Asambodo

YTBIO na-agba mbọ inye ndị ahịa ihe dị ọcha kacha mma Tirzepatide ntụ ntụ nnukwu na ọrụ ka onye ọ bụla na-azụ ahịa nwee ike ịnụ ụtọ nri eke, ahụike yana oke mma. Ọ bụrụ na ị nwere ajụjụ ọ bụla ma ọ bụ mkpa gbasara ngwaahịa anyị, biko nweere onwe gị ịkpọtụrụ anyị, anyị ga-azaghachi gị ozugbo enwere ike.

Ngwugwu & Mbupu

Ụlọ ọrụ anyị na ụlọ ọrụ mmepụta ihe